This case report presents the long-term course of treatment of 77-year old women with metastatic hormonoresponsive, HER2-positive breast cancer. The patient has been treated with surgery, radiotherapy, hormonal therapy, chemotherapy and agents targeting HER2. Overall treatment was well tolerated and control of symptoms associated with disease, as well as partial objective response was achieved. . Due to treatment individualization, modifications of chemotherapy doses and regimens antineoplastic therapy in this elderly women was safe and effective. She benefits from the treatment in terms of significant quality of life improvement and prolongation of survival.Prezentowany przypadek przedstawia wieloletni przebieg leczenia, obecnie 77-le...
About 75% of breast cancers are estrogen receptor-positive. Approximately 10% of them is HER2-positi...
Systemic adjuvant treatment has established role in the treatment of breast cancer and anthracycline...
Metastatic at diagnosis breast cancer occurs increasingly rarely, yet it remains a significant thera...
Breast cancer is the most common women neoplasm. Despite standard primary treatment, there are quite...
The choice of treatment modality in metastatic breast cancer depends on an age, performance status o...
Rak piersi jest najczęstszym kobiecym nowotworem złośliwym, w związku z czym stanowi bardzo istotny ...
Capecitabine monotherapy represents an effective and feasible option in heavily pretreated women wit...
Breast cancer is the most common caner occurring in women in Poland.Hormone therapy in palliative tr...
We are presenting a case of an elderly woman diagnosed with ovarian cancer, treated in Department of...
Leczenie onkologiczne chorych w podeszłym wieku wymaga podstawowej znajomości zagadnień geriatryczny...
Trastuzmab is the treatment of choice for HER2-overexpressing metastatic breast cancer. The treatmen...
Z roku na rok coraz więcej kobiet w podeszłym wieku z istotnym obciążeniem internistycznym choruje n...
Rak piersi jest najczęściej występującym nowotworem złośliwym wśród kobiet w Polsce. Rocznie z jego ...
Breast cancer is the most frequent cancer in women and the second cause of cancer-related deaths in ...
Lapatinib in combination with capecitabine is an effective treatment modality in metastatic HER2-pos...
About 75% of breast cancers are estrogen receptor-positive. Approximately 10% of them is HER2-positi...
Systemic adjuvant treatment has established role in the treatment of breast cancer and anthracycline...
Metastatic at diagnosis breast cancer occurs increasingly rarely, yet it remains a significant thera...
Breast cancer is the most common women neoplasm. Despite standard primary treatment, there are quite...
The choice of treatment modality in metastatic breast cancer depends on an age, performance status o...
Rak piersi jest najczęstszym kobiecym nowotworem złośliwym, w związku z czym stanowi bardzo istotny ...
Capecitabine monotherapy represents an effective and feasible option in heavily pretreated women wit...
Breast cancer is the most common caner occurring in women in Poland.Hormone therapy in palliative tr...
We are presenting a case of an elderly woman diagnosed with ovarian cancer, treated in Department of...
Leczenie onkologiczne chorych w podeszłym wieku wymaga podstawowej znajomości zagadnień geriatryczny...
Trastuzmab is the treatment of choice for HER2-overexpressing metastatic breast cancer. The treatmen...
Z roku na rok coraz więcej kobiet w podeszłym wieku z istotnym obciążeniem internistycznym choruje n...
Rak piersi jest najczęściej występującym nowotworem złośliwym wśród kobiet w Polsce. Rocznie z jego ...
Breast cancer is the most frequent cancer in women and the second cause of cancer-related deaths in ...
Lapatinib in combination with capecitabine is an effective treatment modality in metastatic HER2-pos...
About 75% of breast cancers are estrogen receptor-positive. Approximately 10% of them is HER2-positi...
Systemic adjuvant treatment has established role in the treatment of breast cancer and anthracycline...
Metastatic at diagnosis breast cancer occurs increasingly rarely, yet it remains a significant thera...